PAH patients may ditch frequent inhaler for Once-a-Day pill
NCT ID NCT07356375
First seen Jan 22, 2026 · Last updated May 23, 2026 · Updated 21 times
Summary
This study follows adults with pulmonary arterial hypertension (PAH) whose doctor decides to switch them from an inhaled medication (iloprost, used several times a day) to an oral pill (selexipag). Researchers will measure changes in quality of life, treatment satisfaction, and how well patients stick with the new medicine. No experimental drugs are involved—all treatments are part of standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION PAH are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.